Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Latest Information Update: 08 Apr 2024
At a glance
- Drugs Lenalidomide (Primary)
- Indications Smoldering multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 04 Apr 2024 This trial has been completed in Ireland.
- 08 Mar 2024 Planned End Date changed from 20 Jul 2027 to 7 Mar 2025.
- 09 Apr 2020 Planned primary completion date changed from 15 Mar 2020 to 15 Mar 2021.